Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Executive Summary
Likely candidates for use of Gilead's priority review vouchers include GS-4997, a Phase III candidate for NASH, and bictegravir, its second-generation integrase inhibitor for HIV. The virology specialist previously used a PRV successfully to accelerate approval of Odefsey.
You may also be interested in...
Deals Of The Year: Cast Your Vote For Top Financing Of 2017
It's time for In Vivo's 10th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners. (It's free.)
ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow
Pricing of $31,000 annually for GSK/J&J's single-tablet, two-drug HIV regimen Juluca (dolutegravir/rilpivirine) is on par with marketed fixed-dose combinations that include integrase inhibitors.
Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen
The latest HIV drug development news and highlights from our FDA Performance Tracker.